Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2016

01-10-2016 | Original Article

Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations

Authors: Isabelle Mahé, Didier Mayeur, Ivan Krakowski

Published in: Supportive Care in Cancer | Issue 10/2016

Login to get access

Abstract

Purpose

Venous thromboembolism (VTE) is one of the most frequent events associated with cancer, requiring hospitalization and generating additional healthcare costs. To date, no studies analyzing the additional costs resulting from VTE associated with cancer in France have been published. The objective of this study was to provide an estimation of the additional cost induced by VTE with cancer by analyzing hospital stays reported in the 2013 PMSI French Hospital Database (“Programme de Médicalisation des Systèmes d’Information”, a national hospital administrative database) for four cancer types (breast, lung, hepatocellular carcinoma, and colon).

Methods

The analysis is divided into three parts: a descriptive evaluation of hospitalizations for VTE with cancer, an analysis by severity level of diagnosis-related groups (DRG), and an estimation of the hospital costs based on the National Reference Costs (ENC). The French public ATIH (“Agence Technique de l’Information sur l’Hospitalisation”, a national Agency for Data on Hospital Care) database was used. The critical approach of this study is based on analysis of the distribution of stays according to levels of severity of DRG.

Results

A total of 14,251 hospitalizations were analyzed combining VTE and cancer. Hospitalizations of the two highest levels of severity (levels 3 and 4) for VTE with cancer represented 81.7 % of all hospitalizations in this population. Increased costs were seen for all four cancer types evaluated, with cost coefficients ranging from 1.34 to 2.01. For example, the average cost of lung cancer in cancer patients with VTE in the PMSI database was 7296 € versus 4647 € in the ATIH database. Cost coefficients were calculated, ranging from 1.34 in colon cancer, 1.50 for breast cancer, 1.57 in lung cancer, and 2.01 for hepatocellular carcinoma.

Conclusion

As discussed in the article, the current costs are high. Better physician adherence to clinical practice guidelines could potentially reduce these costs by lowering the number of recurrent VTE in patients with cancer.
Literature
1.
Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722CrossRefPubMed
2.
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453SCrossRefPubMed
3.
Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRefPubMed
4.
Hanna N, Bikov KA, McNally D, Onwudiwe NC, Dalal M, Mullins CD (2012) Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer. Oncologist 17(9):1191–1197CrossRefPubMedPubMedCentral
5.
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SCrossRefPubMed
6.
Thromboembolic Tisk Factors (THRIFT) Consensus Group (1992) Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 305:567–574
7.
Cohen AT (2002) Discoveries in thrombosis care for medical patients. Semin Thromb Hemost 28(Suppl 3):13–17CrossRefPubMed
8.
Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(no. 2):pp. 146–pp. 153CrossRef
9.
Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clin Outcomes Res CEOR 5:101–108CrossRef
10.
Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488CrossRefPubMed
11.
12.
Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M, Investigators RIETE (2013) Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 131(1):24–30CrossRefPubMed
13.
14.
15.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost JTH 11(no. 1):pp. 56–pp. 70CrossRef
16.
Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S (2012) All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm JMCP 18(5):363–374PubMed
17.
18.
Scotte F, Martelli N, Vainchtock A, Borget I (2015) The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. Adv Ther 32(2):138–147CrossRefPubMed
19.
Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm JMCP 13(6):475–486PubMed
20.
Lang K, Patel AA, Munsell M, Bookhart BK, Mody SH, Schein JR, Menzin J (2015) Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis. J Thromb Thrombolysis 39(4):434–442CrossRefPubMed
21.
Sevestre MA, Belizna C, Durant C, Bosson J-L, Vedrine L, Cajfinger F, Debourdeau P, Farge D, Carmen Investigators for the Groupe Francophone Thrombose et Cancer (GFTC) (2014) Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 39(3):161–168CrossRefPubMed
22.
Huang W, Anderson FA, Rushton-Smith SK, Cohen AT (2015) Impact of thromboprophylaxis across the US acute care setting. PloS One 10(no. 3):p. e0121429CrossRef
23.
Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H (2015) Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol p. JCO.2014.55.1481
24.
MacLellan DG, Richardson A, Stoodley MA (2012) Venous thromboembolism and cancer. ANZ J Surg 82(5):294–298CrossRefPubMed
25.
Mahé I, Puget H, Buzzi JC, Lamuraglia M, Chidiac J, Strukov A, Helfer H, Perozziello A (2016) Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study. Support Care Cancer. doi:10.​1007/​s00520-016-3164-8
Metadata
Title
Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations
Authors
Isabelle Mahé
Didier Mayeur
Ivan Krakowski
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3224-0

Other articles of this Issue 10/2016

Supportive Care in Cancer 10/2016 Go to the issue

Original Article

Quality of life-related outcomes from a patient-tailored integrative medicine program: experience of Russian-speaking patients with cancer in Israel

Original Article

Prevalence and associates of psychological distress in haematological cancer survivors

Original Article

Patient and health care provider perceptions of cancer-related fatigue and pain

Original Article

The palatability of oral nutritional supplements: before, during, and after chemotherapy

Original Article

Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

Erratum

Erratum: Erratum to: Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits